

Targeting protein-protein interactions for new cancer therapeutics

Targeting protein-protein interaction using non-peptidic small-molecule inhibitors is a challenging task in modern drug discovery and medicinal chemistry. This seminar will present the structure-based design and optimization of a class of potent and non-peptidic small-molecules to target the MDM2-p53 protein-protein interaction as a new class of anti-cancer drugs, and extensive biochemical, biological and pharmacological evaluations.